Precision Therapeutics will present data on four compelling multi-gene breast cancer signatures at the 2011 Breast Cancer Symposium, being held September 8-10, 2011, in San Francisco, California. Precision’s abstract, titled, “Evaluation of the Performance of Breast Cancer Cell-Line Derived Multi-Gene Predictors (MGPs) of Chemotherapy Response in Multiple Clinical Trials,” demonstrates the feasibility of using these signatures to predict chemotherapy response in breast cancer patients.  “The promising results give us hope for helping optimize treatments for breast cancer patients.” says Nan Song, Bioinformatics and Statistic Scientist at Precision Therapeutics. Learn more atwww.precisiontherapeutics.com.